Design and Synthesis of New 1,3,5‐Trisubstituted Triazines for the Treatment of Cancer and Inflammation-Reference-Cited by-同舟云学术

Design and Synthesis of New 1,3,5‐Trisubstituted Triazines for the Treatment of Cancer and Inflammation

Published:2018-09 Issue:9 Volume:7 Page:737-749
ISSN:2191-1363
Container-title:ChemistryOpen
language:en
Short-container-title:ChemistryOpen

Author:

Zacharie Boulos¹^ORCID,Abbott Shaun D.¹,Duceppe Jean‐Simon¹,Gagnon Lyne¹,Grouix Brigitte¹,Geerts Lilianne¹,Gervais Liette¹,Sarra‐Bournet François¹,Perron Valérie¹,Wilb Nicole¹,Penney Christopher L.¹,Laurin Pierre¹

Affiliation:

1. Prometic Biosciences Inc. 500 boul. Cartier Ouest, Bureau 150 Laval Québec H7V 5B7 Canada

Funder

Prometic Life Sciences Inc.

Publisher

Wiley

Subject

General Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/open.201800136

Reference55 articles.

1. Discovery of small molecule cancer drugs: Successes, challenges and opportunities

2. Prospective identification of tumorigenic breast cancer cells

3. Challenges, controversies, breakthroughs

4. Recent progress in pancreatic cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and apoptotic activity of substituted chalcones tethered 1,3,5-triazine hybrids: An insights from molecular docking, molecular dynamics simulations, DFT, ADME, and DAPI analyses;Journal of Molecular Structure;2024-11

2. An operationally simple, one‐pot, convenient synthesis, and in vitro anti‐inflammatory activity of some new spirotriazolotriazine derivatives;Journal of Heterocyclic Chemistry;2023-11-08

3. Synthesis and Characterizations of Novel Isatin-s-Triazine Hydrazone Derivatives; X-ray Structure, Hirshfeld Analysis and DFT Calculations;Crystals;2023-02-12

4. Recent updates on 1,2,3‐, 1,2,4‐, and 1,3,5‐triazine hybrids (2017–present): The anticancer activity, structure–activity relationships, and mechanisms of action;Archiv der Pharmazie;2022-11-13

5. Recent Advances in the Biological Activity of s-Triazine Core Compounds;Pharmaceuticals;2022-02-12